These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34548375)

  • 1. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review.
    Ugarte-Gil MF; Mendoza-Pinto C; Reátegui-Sokolova C; Pons-Estel GJ; van Vollenhoven RF; Bertsias G; Alarcon GS; Pons-Estel BA
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34548375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
    Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
    Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for cardiovascular diseases in patients with systemic lupus erythematosus: an umbrella review.
    Katayama Y; Yanai R; Itaya T; Nagamine Y; Tanigawa K; Miyawaki Y
    Clin Rheumatol; 2023 Nov; 42(11):2931-2941. PubMed ID: 37142864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of overweight and obesity on disease activity and remission in systemic lupus erythematosus: A systematic review and meta-analysis protocol.
    Medeiros MCS; Souza KSC; Galdino OA; Cobucci RN; de Rezende AA
    PLoS One; 2023; 18(6):e0287753. PubMed ID: 37384711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis.
    Giambalvo S; Garaffoni C; Silvagni E; Furini F; Rizzo R; Govoni M; Bortoluzzi A
    Autoimmun Rev; 2022 Apr; 21(4):103038. PubMed ID: 34995765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, Predictors, and Prognostic Benefits of Remission Achievement in Patients With Systemic Lupus Erythematosus: A Systematic Review.
    Yang Z; Cheng C; Wang Z; Wang Y; Zhao J; Wang Q; Tian X; Hsieh E; Li M; Zeng X
    Arthritis Care Res (Hoboken); 2022 Feb; 74(2):208-218. PubMed ID: 32986933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis.
    Murimi-Worstell IB; Lin DH; Nab H; Kan HJ; Onasanya O; Tierce JC; Wang X; Desta B; Alexander GC; Hammond ER
    BMJ Open; 2020 May; 10(5):e031850. PubMed ID: 32444429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treat to target in systemic lupus erythematosus: a commentary.
    Ugarte-Gil MF; Burgos PI; Alarcón GS
    Clin Rheumatol; 2016 Aug; 35(8):1903-1907. PubMed ID: 27406378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Ferro F; Parma A; Carli L; Signorini V; Zucchi D; Peta U; Santoni A; Raffaelli L; Mosca M
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32075876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicidal behavior in patients with systematic lupus erythematosus: Systematic literature review and genetic linkage disequilibrium analysis.
    Parperis K; Kyriakou A; Voskarides K; Chatzittofis A
    Semin Arthritis Rheum; 2022 Jun; 54():151997. PubMed ID: 35344734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.
    Perea-Seoane L; Agapito-Vera E; Gamboa-Cardenas RV; Guzmán-Sánchez G; Pimentel-Quiroz VR; Reategui-Sokolova C; Medina M; Elera-Fitzcarrald C; Noriega E; Rodriguez-Bellido Z; Pastor-Asurza C; Perich-Campos R; Alarcón GS; Ugarte-Gil MF
    Lupus; 2022 Jan; 31(1):110-115. PubMed ID: 34969318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.